Pharmacological evaluation of delta2, 1,2,4-triazolin-5-one [1,3(4-m-chlorophenyl-1-piperazinyl)-propyl]-3,4-diethyl-hydrochloride (Etoperidone), a new potential antidepressant drug.
D000700:Analgesics; D000818:Animals; D000927:Anticonvulsants; D000928:Antidepressive Agents / Q000494:pharmacology* / Q000633:toxicity; D001522:Behavior, Animal / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D002415:Cats; D004285:Dogs; D004347:Drug Interactions; D005260:Female; D006168:Guinea Pigs; D006439:Hemodynamics / Q000187:drug effects; D006591:Hexobarbital / Q000494:pharmacology; D066298:In Vitro Techniques; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects; D010879:Piperazines / Q000494:pharmacology* / Q000633:toxicity; D011817:Rabbits; D051381:Rats; D012890:Sleep / Q000187:drug effects; D013894:Thirst / Q000187:drug effects; D014230:Triazoles / Q000494:pharmacology*
D000700:Analgesics; D000927:Anticonvulsants; D000928:Antidepressive Agents; D010879:Piperazines; D014230:Triazoles; D006591:Hexobarbital